Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer.
Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer.
复制标题
DOI：
10.1158/1940-6207.capr-09-0143
复制
发表时间：
2010-08
期刊：
影响因子：
--
通讯作者：
Ahmann FR
中科院分区：
文献类型：
--
作者：
Stratton MS;Algotar AM;Ranger-Moore J;Stratton SP;Slate EH;Hsu CH;Thompson PA;Clark LC;Ahmann FR
癌症的营养预防试验表明，补充硒的男性前列腺癌的发病率降低了52%。因此，我们的研究旨在评估硒补充剂是否能减缓前列腺癌的进展。在选择放弃积极治疗并接受积极监测的局部非转移性前列腺癌男性中进行了一项II期随机、双盲、安慰剂对照临床试验。共有140名男性被随机分配到安慰剂组（n = 46）、200 μ g/天（n = 47）或800 μ g/天（n = 47）硒口服组。(as硒化酵母），每3个月随访一次，持续5年。PSA速度被用作前列腺癌进展的标志物，并使用混合效应回归进行估计。校正年龄、体重指数、基线硒、吸烟、基线PSA、种族、PSA方法和Gleason评分; 200 μ g/天和800 μ g/天治疗组的PSA速度与安慰剂组无统计学显著差异（分别为p = 0.32和p = 0.61）。在基线硒的最高四分位数中，与安慰剂相比，补充800 μ g硒的男性显示PSA速度在统计学上显著更高（p = 0.018）。在局限性前列腺癌患者中，补硒对PSA速度没有保护作用。相反，在基线血浆硒浓度高的男性中，观察到补充高剂量硒是PSA速度增加的风险因素。clinicaltrials.gov
The Nutritional Prevention of Cancer Trial demonstrated a 52% lower incidence of prostate cancer in men supplemented with selenium. As a result, our study was designed to assess whether selenium supplementation attenuates the progression of prostate cancer. A Phase 2 randomized, double-blind, placebo-controlled clinical trial was conducted in men with localized non-metastatic prostate cancer who had elected to forgo active treatment and be followed by active surveillance. A total of 140 men were randomized to placebo (n=46), 200 μg/day (n=47) or 800 μg/day (n=47) selenium p.o. (as selenized yeast) and followed every 3 months for up to 5 years. PSA velocity was used as a marker of prostate cancer progression and was estimated using mixed effects regression. Adjusting for age, body mass index, baseline selenium, smoking, baseline PSA, race, PSA method, and Gleason score; PSA velocities for 200 μg/day and 800 μg/day treatment groups were not statistically significantly different from placebo (p = 0.32 and p = 0.61 respectively). In the highest quartile of baseline selenium, men supplemented with 800 μg selenium demonstrated PSA velocity statistically significantly higher as compared to placebo (p = 0.018). Selenium supplementation did not show a protective effect on PSA velocity in subjects with localized prostate cancer. On the contrary, supplementation with high dose selenium was observed to be a risk factor for increased PSA velocity in men with high baseline plasma selenium concentrations. clinicaltrials.gov (NCT00752739)